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SUMMARY
Introduction: Helicobacter pylori is a bacteria which infects half the world population and is an important cause of gastric 
cancer. The eradication therapy is not always effective because resistance to antimicrobials may occur. The aim of this study was to 
determine the susceptibility profile of H. pylori to amoxicillin, clarithromycin and ciprofloxacin in the population of Southern Brazil. 
Material and methods: Fifty four samples of H. pylori were evaluated. The antibiotics susceptibility was determined according to 
the guidelines of the British Society for Antimicrobial Chemotherapy and the Comité de l’Antibiogramme de la Société Française de 
Microbiologie. Results: Six (11.1%) H. pylori isolates were resistant to clarithromycin, one (1.9%) to amoxicillin and three (5.5%) to 
ciprofloxacin. These indices of resistance are considered satisfactory and show that all of these antibiotics can be used in the empirical 
therapy. Conclusion: The antibiotics amoxicillin and clarithromycin are still a good option for first line anti-H. pylori treatment in 
the population of Southern Brazil.
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INTRODUCTION 
Helicobater pylori (H. pylori) is a bacterial agent affecting more than 
80% of the population of developing countries and therapy schedules 
have not always been effective in such cases16. One of the possible 
explanations for failures in eradicating it is the bacterial resistance to the 
used antimicrobial or the utilized antibiotics concentration. 
The susceptibility of H. pylori to antibiotics can be quite variable 
in particular geographical areas of the same country as well as among 
different countries, being directly influenced by the previous use of these 
medications. Thus, the success of a scheme of treatment in a community 
does not enable the generalization of the results13. It would be ideal 
to provide a therapy based on previous knowledge of the microbial 
resistance rate in a local community, which has been difficult in most 
centers of developing countries14. 
Classically, the treatment consists of the association of amoxicillin 
and clarithromycin with a proton pump inhibitor21. This is one of the 
first choice therapeutic purposes and is recommended by the II Brazilian 
Consensus on H. pylori5. Other antimicrobials, as quinolones, are 
useful therapeutically, but they are normally considered for second line 
treatments.
There are few Brazilian studies, and none in Southern Brazil (State 
of Rio Grande do Sul), that have demonstrated rates of resistance to 
antibiotics, and not knowing this information has complicated the 
therapeutic success. This way, this research aims to define the profile 
of susceptibility of H. pylori to antibiotics widely utilized as a first 
line treatment, amoxicillin and clarithromycin, and also a second line 
antibiotic, quinolones, along the population of Rio Grande do Sul, Brazil. 
MATERIAL AND METHODS
Patients: A total of 342 patients were included, ranging in age from 
18 to 80 years old, with a clinical indication for the realization of upper 
digestive endoscopy at the Clinical Hospital of Porto Alegre, in Southern 
Brazil. Individuals excluded from this study were: the ones presenting 
gastric cancer or those who were undergoing treatment for any kind 
of cancer, considering their total or partial gastrectomia, cirrhosis in 
critical condition, decreasing of blood platelets or if they were using 
anticoagulants, presenting indication of esophageal dilatation or passage 
of probe, nephropathy in critical condition, esophageal varicose veins or 
ligation of esophageal varicose veins. 
Biopsy sampling and bacterial strains: The samples were collected 
between January 2011 and January 2012. Three gastric antral biopsy 
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specimens were obtained for each patient during endoscopy. One of 
them underwent a rapid urease test, the other was sent to histological 
examination, and the other for culture. For the cultivation, the biopsy 
specimens were sent to the laboratory within three hours of being 
collected, in Eppendorf sterile tubes containing 0.1 mL of physiological 
solution. Each biopsy specimen was seeded on to Agar Belo Horizonte 
(Probac of Brazil, Brazil) and incubated in microaerobic conditions 
(Microaerobac, Probac of Brazil), at 37 °C, for five days. The growth 
suggestive of H. pylori (small, circular and bright colonies) was 
identified through universally accepted phenotypic proofs: morphology 
characteristic in Gram’s stained smears (Gram negative rod curved or in 
“S”), positive urease, positive catalase and positive oxidase22,23.
The cultures correspondent to H. pylori were subcultured in 
Agar Columbia Chocolate (Oxoid, United Kingdom) along with 0.1 
mL of Brain Heart Infusion broth (Himedia, India) and incubated in 
microaerobic conditions (Miacroaerobac, Probac of Brazil), stored at 
37 °C, during three days. The abundant and fresh growth of the bacteria 
was utilized for antimicrobial susceptibility tests.
Determination of antimicrobial susceptibility: The susceptibility 
to antibiotics was defined in 54 strains with culture positive according 
to the standards of the British Society for Antimicrobial Chemotherapy 
(BSAC)3 and the Committee of l’Antibiogramme of la Société Française 
of Microbiologie (CA-SFM)6. Several colonies were suspended from 
H. pylori of each sample in some sterile diluent until equivalence to 
pattern 3 of McFarland standard. The suspensions were inoculated 
with sterile swabs onto the surface of Agar Mueller Hinton (Oxoid, 
United Kingdom) 10% horse blood until drying. The antibiotics applied 
were: E-test amoxicillin strips of and E-test clarithromycin strips, both 
with gradient of concentration of 0.016 until 256 µg/mL and disks of 
ciprofloxacin 5 µg. The plates were incubated at 37 °C, in microaerobic 
conditions (Microaerobac, Probac of Brazil), from three to four days. The 
minimum inhibitory concentrations (MIC) of amoxicillin (AMO) and 
clarithromycin (CLA) were read in the point where the zone of elliptic 
inhibition intercepted the E-test strip. The diameter of the inhibition zone 
was measured for ciprofloxacin (CIP), promoted by the diffusion of the 
antibiotic contained in the disk.
The criteria for the definition of resistance according to each standard 
were the following: AMO (MIC > 1 µg/mL) and CLA (MIC > 1 µg/mL)5, 
CIP (diameter of inhibition zone < 20 mm)6. 
The Committee of Ethics in Research of the Hospital de Clínicas de 
Porto Alegre approved this study (number 07-654), and all the participants 
signed an informed consent.
RESULTS
The resistance to CLA was detected in six of 54 (11.1%) strains of 
H. pylori (Table 1), considering that three of them expressed high level 
of resistance to antibiotic, with MICs equal or greater than 256 µg/mL. 
The other strain presented MICs of 8, 24 and 32 µg/mL for this antibiotic.
The resistance to AMO was found in only one strain (1.9%) of 
H. pylori (Table 1) and being compatible to a low level of resistance 
expression (MIC 2 µg/mL). The strain resistant to AMO presented 
simultaneous resistance to CLA (Table 2) (MIC 24 µg/mL). 
The rate of resistance to CIP was 5.5% (3 samples) (Table 1). One 
strain resistant to CIP presented simultaneous resistance to CLA (Table 
2) (MIC > 256 µg/mL). 
DISCUSSION
This study demonstrated that the rates of resistance of H. pylori to 
antibiotics usually utilized as first line therapy were satisfactory, with 
rates practically null for AMO and low for CLA and for CIP. 
The therapeutic failure for eradication treatment of H. pylori 
infections may be multifactorial, but the antimicrobial resistance is the 
main reason for the treatment failure14. The susceptibility of H. pylori to 
antibiotics has demonstrated variations between different locations and 
it has been influenced by the previous use of these drugs. Therefore, it 
becomes relevant to base the treatment on previous knowledge about 
the antimicrobial resistance rate in the local community14, promoting 
the most rational use of antibiotics.
In 8 (14.8%) of 54 strains of H. pylori, the resistance was found in at 
least one of the tested antibiotics (Table 2), and the lowest frequency of 
this event was associated with AMO (1.9%). Currently, the world rates 
of resistance to this antibacterial have been low and, for this reason, the 
same has been frequently utilized in the combined first line therapy. In 
countries of Latin America, rates of resistance to AMO were reported as 
less than 4%, being 3.8% in Colombia29, 2.2% in Paraguay10 and 2.3% 
in Chile23. There was no resistance to this antibiotic in Venezuela30, São 
Paulo/Brazil9 and in any other Colombian work2. The susceptibility to 
AMO has been also high in other countries as Germany34, Spain8,18, 
Philippines7 and Tunisia20. Even if the susceptibility of H. pylori to 
AMO may be very satisfactory, it is important to monitor it, once high 
resistance rates have been found in some locations 1.
Table 1.
Profile of susceptibility of 54 isolates of H. pylori to antibiotic
Antibiotics Resistant isolates of H. pylori n (%)
 MIC 
(µg/mL)
Amoxicillin (AMO) 1 (1.9) < 0.016 - 2
Clarithromycin (CLA) 6 (11.1) < 0.016 - > 256
Ciprofloxacin (CIP) 3 (5.5) Non-applicable
MIC: Minimum Inhibitory Concentration; µg/mL: microgram/milliliter.
Table 2. 
Resistance profiles of eight H. pylori strains with some resistance to 
antibiotics 
Resistance profiles n 
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Fortunately, beyond the rate of resistance to AMO found in this study 
being low (1.9%), the level of expression of such resistance was also 
undermost, not overcoming the MIC of 2 µg/mL. On the other hand, in 
Chile, despite of rates of resistance to AMO being low (2.3%) strains 
with expressive level of resistance were found with MIC greater than 
256 µg/mL23.
In this study, six strains (11.1%) of H. pylori were resistant to CLA. 
World data has demonstrated that the rates of resistance to CLA presented 
geographical variations. Data reviewed by WANG et al. (2000) has 
indicated levels of resistance of 9.1% in Japan, from 6.1 to 12.6% in the 
United States and less than 15% in Europe33. 
In Latin America, many studies reported variable resistance 
frequencies to CLA, ranging between 2.2% and 17.7% in Colombia2,15,29, 
between 9.1%23 and 20%31 in Chile and 2.2% in Paraguay10. In Brazil, 
rare studies realized have also demonstrated variable rates: in São Paulo 
from 8%9 to 16%25, in Belo Horizonte 17.3%19 and 16.5% in Recife17.
The diversity in the rates of resistance to CLA may be attributed to 
different frequencies of the utilization of this antibiotic in different world 
geographical areas. It has been proved that the previous use of macrolides, 
as erythromycin and azithromycin, have induced cross-resistance to CLA. 
On the other hand, the resistance to CLA decreased the efficacy of the 
antibiotic therapy and it has been the main risk factor for therapeutic 
failure. In lineages of H. pylori, sensitive to this antibacterial, the rates 
of eradication have approximated to 88%24. The literature has considered 
that antibiotics which rates of resistance have overcome 20% must not 
be used in the therapy of anti-H. pylori11.
Among the six H. pylori strains resistant to CLA reported in this 
study, three presented high level of resistance to this antibiotic, with 
MICs equal or greater than 256 µg/mL. Such finding has suggested the 
previous utilization of macrolides by the population evaluated in our 
study, generated cross-resistance to CLA in very expressive levels. Still, 
Chilean work carried out by OTTH et al. revealed that all eight samples 
of H. pylori resistant to CLA had maximum MICs of 64 µg/mL23. 
Ciprofloxacin (CIP) may be prescribed to individuals allergic to 
AMO or to those that present failure in the triple therapy26. The world 
levels of resistance to CIP have been relatively low, reaching 2.4% in 
Teheran/Iran27, 5.7% in Chile23, 7.9% in Spain28 and 9.5% in Germany12. 
Similarly, the data of this study also revealed a reduced rate of H. pylori 
resistance to CIP (5.5%). This finding has revealed the possibility of its 
employment in eradication therapy, in case the utilization of antibiotics 
not belonging to the first line treatment may be necessary in the population 
of Rio Grande do Sul, Brazil. On the other hand, the highest resistance 
rates to CIP have been reported in China (55.7%)32, Iran (35%)1 and 
Portugal (21%)4.
Due to the low rates of resistance to antibiotics found in this study, 
AMO and CLA may be used empirically in anti-H. pylori therapy in 
the State of Rio Grande do Sul, respecting the recommendations of the 
II Brazilian Consensus Conference on H. pylori. However, due to the 
simultaneous resistance to more than one antimicrobial in two isolates 
of bacteria (one to CLA+AMO and the other to CLA+CIP), it has been 
suggested the necessity of establishing a surveillance system in order 
to prevent treatment failures and the spread of resistant strains. This 
surveillance would also be important to establish whether these resistant 
strains represent sporadic cases or correspond to an usual behavior in a 
given geographical region.
RESUMO
Resistência à amoxicilina, claritromicina e ciprofloxacina de 
Helicobacter pylori isolados de pacientes do Sul do Brasil
Introdução: Helicobacter pylori é uma bactéria que infecta metade 
da população mundial e é considerada importante causa de câncer 
gástrico. A terapia de erradicação nem sempre é eficaz, pois pode 
ocorrer a resistência aos antimicrobianos. Este estudo determinou 
a sensibilidade de H. pylori frente à amoxicilina, claritromicina e 
ciprofloxacina na população do Sul do Brasil. Material e métodos: 
Foram avaliadas 54 amostras de H. pylori. A sensibilidade aos 
antibióticos foi determinada segundo as orientações da British Society 
for Antimicrobial Chemotherapy e do Comité de l’Antibiogramme 
de la Société Française de Microbiologie. Resultados e discussão: 
Sete (13%) isolados de H. pylori foram resistentes à claritromicina, 
um (1,9%) à amoxicilina e três (5,5%) à ciprofloxacina. Estes índices 
são satisfatórios e demonstram que esses antibióticos podem ser 
utilizados na terapia empírica. Conclusão: Os antibióticos amoxicilina 
e claritromicina ainda são uma boa opção no tratamento de primeira 
linha anti-H. pylori na população do Sul do Brasil.
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